Find information on thousands of medical conditions and prescription drugs.
Keratoacanthoma
Keratoacanthoma is a rapidly appearing "self-healing" variety of squamous cell carcinoma. To be safe, they are usually treated by dermasurgeons with an excisional biopsy.
Generalized eruptive keratoacanthoma of Grzybowski - Case Reports Abstract We describe the case of a 71-year-old woman with a six-year history of generalized eruptive keratoacanthomas on the extremities. We review ... From Journal of Drugs in Dermatology,
6/1/03
by David H. Chu
Keratoacanthoma arising from an excisional surgery scar Abstract A causal relationship between keratoacanthomas and a variety of preceding traumatic events has been postulated in the literature. We report ... From Journal of Drugs in Dermatology,
3/1/04
by Arash Kimyai-Asadi
Imiquimod as a possible treatment for keratoacanthoma - Case Reports Abstract Imiquimod is an immune-response modifier that has the potential to be useful in many dermatological indications (Table 1). To date, the approved ... From Journal of Drugs in Dermatology,
1/1/04
by Neal Bhatia
Malignant melanoma Malignant melanoma is a type of skin tumor that is characterized by the cancerous growth of melanocytes, which are cells that produce a dark pigment called ... From Gale Encyclopedia of Medicine,
4/6/01
by Cindy L. Jones
Pancytopenia after a single intradermal infiltration of methotrexate Abstract Methotrexate-related hematologic toxicity may include leakopenia, thrombocytopenia, megaloblastic anemia, and pancytopenia. We report a woman ... From Journal of Drugs in Dermatology,
9/1/05
by Philip R. Cohen
Chondrodermatitis nodularis chronica helicis Chondrodermatitis nodularis chronica helicis is a small, painful, scaly nodule of the helix of the ear. It was first described by Winkler in 1915, and ... From Ear, Nose & Throat Journal,
7/1/05
by Sofia Avitia
Merkel cell carcinoma in a patient with autoimmune hepatitis Abstract Merkel cell carcinoma (MCC) has been shown to have a higher incidence in many etiologically distinct immunosuppressed populations. We report ... From Journal of Drugs in Dermatology,
5/1/05
by Joseph Lillis